ToxGenSolutions

Toxicity tests, preclinical diagnostics and preventive therapeutics for three high impact pathologies triggered by environmental factors

(Epi-)genetic approaches addressing molecular initiation events and key events of adverse outcome pathways driving pathologies like neurodegeneration, cancer and immune-dysfunction

Breaking News and Latest Headlines

  • ToxGenSolutions BV identified a 9 miR periferal profile that can identify individuals at risk for acquiring late-onset Alzheimer’s Disease years in advance

    This proposal addresses the objective to drive the development of cutting-edge biomarkers and to explore novel diagnostic technologies.

    The ultimate goal of our program is to make diagnosis of late-onset Alzheimer’s Disease (AD):

    1. faster by turning the months/years it takes for the current diagnostic approach into hours,
    2. cheaper by eliminating expensive scans (e.g., €2,000-€2,500/$3,000-$4,500 for PET scans),
    3. more accurate in the prodromal phase of the disease with currently 50% of individuals diagnosed with mild cognitive impairment (MCI) not developing dementia,
    4. less invasive by replacing CSF sampling with blood sampling (urine as an option).

    Our work-hypothesis: Individuals at risk for progressing into AD must be identified early if future drugs (once available) are to have any effect on the quality of life. Thus, novel biomarkers should reflect processes that are in transition from normal physiology into AD related pathology before neurons start to die off and the brain volume shrinks.

    Next step: The prognostic profile is currently being validated with the support from the EU EuroStars programme. The product will be a biosensor device providing results within 3 hours after the blood/urine sample was taken, with a 90% accuracy according to the data that emerged from a pilot study.

    Outreach: ToxGenSolutions is reaching out to investors and companies active in the field of diagnostics and drug development with the purpose of setting up commercial collaborations.

  • LATEST NEWSLETTER OF THE INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”)

    Unfortunately, the Covid-19 pandemic has also impacted the progress being made by the #Interreg. Vlaanderen-Nederland project ”Herinneringen” (”Memories”). But, progress was made, and the prolongation with 6 months that was approved by #Interreg. will allow us to reach the goal. Read more about it in our latest newsletter.

    https://herinneringen.eu

  • HUMAN SAMPLES SUPPORT THE RELEVANCE OF 20 ‘ENVIRONMENTAL’ miR’s

    Differentially expression analysis of human iPSCs derived neurons, and human brain slices, blood samples and cerebrospinal fluid from Alzheimer’s patients and control individuals has identified 20 potential biomarkers affecting processes and pathways that are relevant for Alzheimer’s disease progression.

    For further information: https://herinneringen.eu/nl

  • FIRST EVIDENCE FOR AN ‘ENVIRONMENTAL’ miR PROFILE FOR SPORADIC ALZHEIMER’S DISEASE

    After several months of lockdown, the Interreg. VL-NL supported project Herinneringen (Memories) was able to finalize the genetic analyses of the human iPSC derived neurons exposed to selected environmental risk factors and biopsies from Alzheimer’s patients and control individuals. Differential gene and pathway analysis revealed processes in patient derived iPSC and biopsies that were not seen in material from control individuals. Currently, 9 miR’s have caught our attention for further evaluation.

  • TOXGENSOLUTIONS RECOGNIZED AS VALUABLE PARTNER FOR INNOVATION AND ENTREPRENEURSHIP IN CHINA

  • DECEMBER 16TH, 2019: 2ND SYMPOSIUM OF THE INTERREG PROJECT ‘MEMORIES’.

    The symposium took place in the very attractive location called Promotie Zaal at the KULeuven which breaths the ancient atmosphere of scientific lectures and thesis defenses over the past centuries.

    During the scientific morning session researchers from the universities of Hasselt, Ghent, Brussels, Leuven and Antwerp provided an update on the current status of Alzheimer’s research in general and within our project. Our understanding of the mechanisms driving the development of Alzheimer’s disease is growing and may result in the discovery of diagnostics and therapeutics.

    The afternoon session targeted the general public. Kim Plasman (Stichting Alzheimer Onderzoek Belgium) Prof. Frans Verhey (University Maastricht), Prof. Sebastiaan Engelborghs (Universiteit of Antwerp) and Prof. Jos Kleinjans (University Maastricht) gave their more general overview about the current knowledge of this neurodegenerative disease. The Dutch journalist and publicist Hugo Borst closed the Symposium with sharing his personal experiences with his mother, who suffered from Alzheimer’s, reading touching passages from his latest book “Ach moedertje”.

  • TOXGENSOLUTIONS REPRESENTED THE INTERREG. PROJECT ”MEMORIES” DURING THE 29th ALZHEIMER’S EUROPE CONGRESS IN THE HAGUE.

    ToxGenSolutions presented a poster showing the approach adopted by the Interreg. project to develop a test for diagnosis of Alzheimer’s disease before it strikes (29th AEC_poster_PO.20.11). The congress was characterized by a high representation of technologies and technological developments that focusses on monitoring the patients. Presentations on scientific progress were limited, and focussing on the clinical phase of disease: ”Looking at Alzheimer’s through the peephole of dementia” as one of the speakers stated. Beside our poster, there was little, if at all, focus on the impact of environmental factors on induction and development of Alzheimer’s.  

  • INTERREG. PROJECT ”HERINNERINGEN”: SYMPOSIUM ‘STOP ALZHEIMER’ on Monday December 16, 2019

    The INTERREG Vlaanderen-Nederland project ”Herinneringen” (”Memories”) organises its 2019 Symposium STOP ALZHEIMER on Monday December 16 in the wonderful ‘Promotiezaal’ of the Katholieke Universiteit Leuven (Naamsestraat 22, 3000 Leuven).
    The programme offers science (in English) and more down-to-earth information (in Dutch) targeting patients, patient organizations and healthcare workers. There will be space for questions, discussion and networking in a relaxed atmosphere.

  • NEWSLETTER: INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”), issue 3

    1. Optimization of in vitro exposure regimes to assure risk factor induced adverse effects in the absence of cytotoxicity.
    2. Hitting the road.

    Newsletter_072019

  • INVITATION TO THE 2019 SYMPOSIUM OF THE INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”)

    The #interreg project #Herinneringen applies #animalfree approaches to understand the #adverseoutcomepathways (#AOP) driving sporadic #alzheimersdisease.

Human Safety and Health based on Human Relevant (Epi-)Genetics

A VIRTUAL GENERIC (EPI-)GENETICS-BASED PLATFORM THAT PROVIDES ANSWERS TO YOUR QUESTIONS ABOUT SAFETY AND EFFICACY OF YOUR PRODUCTS.

NEXT-GENERATION TOOLS

  • A systems-based technology platform for profiling the positive as well as negative impact of compounds and product on (patho-)physiological responses and human health at realistic concentrations and under relevant exposure regimes.

  • Our toolbox contains a breadth of technologies, systems, and pathways and common nodes of toxicity and pathology.

  • The available toolbox is useful for the identification of new opportunities for product development in the chemical, cosmetic, food, diagnostics and pharmaceutical sector.

  • The toolbox is flexible, faster than traditional methods, more economical and more relevant for human safety and health.

FRONT-EDGE TECHNOLOGIES

  • ToxGenSolutions products are proprietary mechanism-based (epi-)genetic signatures for identification and classification of new leads and toxicants during screening, product development and safety assessment.

  • ToxGenSolutions provides a front-edge patchwork of test methods required for modern testing and assessment of compounds and products through tight collaboration with front-runners in the area of human tissue development.

  • ToxGenSolutions exploits the (epi-)genetic data to develop diagnostics for high impact pathologies (e.g. neurodegenerative diseases, cancer, immuno-dysfunction) in a preclinical stage.

FOCUS ON YOUR NEEDS

  • ToxGenSolutions develops testing and assessment strategies for, and with, you to assure optimal coverage of your needs.
  • ToxGenSolutions develops strategies considering the nature of the test substance, the intended application, likely exposure routes, product development status and legislation.

Engaging front-runners in a multidisciplinary approach for a safer future

Future perspectives

Diagnostic devices for high impact pathologies, triggered by environmental risk factors and life style, incorporating artificial intelligence based on big.

Advanced in vitro platform for personalized cancer medicine and treatment using intestinal human tissue, representing a very fast method to test individual  responses to a drug and to determine the safe but effective dosage.

New therapeutic targets allowing for treatment of neurodegenerative diseases in a preclinical stage.

The impact of inflammatory signals on cell-cell communication in the brain using state-of-the-art in vitro methods.

An ontology-driven and artificial intelligence-based strategy, linked with a battery of in vitro assays and in silico tools for hazard prediction, combined with tailored exposure assessment for human risk assessment.

INFORMATION

Do you have any questions to our services then you are welcome to contact us today. Call us or send an email and then we will reply as soon as possible.

CONTACT ADDRESS

ToxGenSolutions B.V.
Oxfordlaan 70
6229 EV Maastricht, The Netherlands

CONTACT US